Profile data is unavailable for this security.
About the company
Polypeptide Group AG is a Switzerland-based Contract Development & Manufacturing Organization (CDMO) focusing on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development as well as in generic products.
- Revenue in CHF (TTM)317.63m
- Net income in CHF-50.30m
- Incorporated2021
- Employees1.20k
- LocationPolyPeptide Group AGNeuhofstrasse 24BAAR 6340SwitzerlandCHE
- Phone+41 435020580
- Websitehttps://www.polypeptide.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kuros Biosciences AG | 33.56m | -13.73m | 341.16m | 80.00 | -- | 5.99 | -- | 10.16 | -0.3697 | -0.3697 | 0.9175 | 1.54 | 0.4347 | 2.40 | 7.27 | 419,550.00 | -17.78 | -13.47 | -21.34 | -14.84 | 71.31 | 78.73 | -40.90 | -81.48 | 1.69 | -84.04 | 0.0364 | -- | 86.61 | 115.93 | 5.95 | -- | -13.21 | -- |
| Idorsia Ltd | 141.42m | -55.88m | 490.18m | 938.00 | -- | -- | -- | 3.47 | -0.3534 | -0.3534 | 0.7363 | -4.97 | 0.1912 | 0.1645 | 113.09 | 150,766.50 | -7.56 | -46.72 | -12.46 | -53.84 | 93.05 | -- | -39.51 | -709.80 | 1.00 | -26.26 | 5.82 | -- | 56.93 | 20.25 | 64.01 | -- | -8.01 | -- |
| Basilea Pharmaceutica AG Allschwil | 157.63m | 10.45m | 575.52m | 147.00 | 49.86 | -- | 47.76 | 3.65 | 0.8765 | 0.8765 | 13.15 | -0.8335 | 0.7999 | 1.06 | 5.16 | 1,072,340.00 | 5.30 | -1.86 | 7.69 | -2.99 | 83.00 | 83.45 | 6.63 | -2.99 | 2.64 | 2.02 | 1.10 | -- | 6.68 | 3.53 | -13.96 | -- | 11.17 | -- |
| Polypeptide Group AG | 317.63m | -50.30m | 1.11bn | 1.20k | -- | 2.95 | -- | 3.48 | -1.52 | -1.52 | 9.59 | 11.31 | 0.5137 | 2.31 | 5.08 | 264,248.20 | -8.13 | 2.59 | -10.37 | 3.26 | 2.81 | 23.73 | -15.83 | 4.58 | 1.12 | -1.56 | 0.2466 | 15.79 | 14.60 | 12.36 | -762.29 | -- | 25.40 | -- |
| Cosmo Pharmaceuticals NV | 94.57m | 1.12m | 1.24bn | 325.00 | 1,016.72 | 2.72 | 81.39 | 13.13 | 0.0696 | 0.0696 | 5.86 | 25.99 | 0.1473 | 3.06 | 2.88 | 290,988.70 | 0.2051 | 0.2437 | 0.249 | 0.267 | 59.33 | 57.28 | 1.39 | 2.10 | 3.80 | 2.73 | 0.0042 | 841.86 | -5.26 | 8.07 | -93.34 | -- | 9.62 | -- |
| BB BIOTECH AG | 270.74m | 307.74m | 2.21bn | -- | 7.11 | 0.8856 | -- | 8.17 | 5.62 | 5.62 | 4.91 | 45.11 | 0.0998 | -- | -- | -- | 11.35 | 2.34 | 12.96 | 2.52 | 97.74 | 99.06 | 113.67 | 35.40 | -- | -- | 0.1223 | 217.78 | -57.97 | -37.98 | 42.26 | -- | -- | -8.09 |
| Dottikon ES Holding AG | 326.27m | 80.63m | 3.67bn | 726.00 | 44.90 | 4.07 | 36.22 | 11.24 | 5.84 | 5.84 | 23.62 | 64.31 | 0.2905 | 0.6518 | 5.23 | 449,407.70 | 7.18 | 7.83 | 8.39 | 8.95 | 66.55 | 75.24 | 24.71 | 24.25 | 1.57 | -- | 0.1014 | -- | 2.13 | 17.17 | -8.08 | 37.75 | 26.82 | -- |
| Siegfried Holding AG | 1.27bn | 112.06m | 4.06bn | 3.93k | 34.21 | 4.55 | 20.91 | 3.19 | 26.28 | 26.28 | 298.23 | 197.49 | 0.6958 | 2.27 | 3.14 | 323,288.60 | 6.17 | 6.51 | 7.67 | 7.98 | 25.20 | 23.24 | 8.86 | 9.06 | 1.39 | 7.93 | 0.3468 | 15.26 | 3.41 | 9.87 | -28.16 | 18.34 | 17.95 | 6.72 |
Data as of Jun 04 2024. Currency figures normalised to PolyPeptide Group AG's reporting currency: Swiss Franc CHF
20.91%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Premier Fund Managers Ltd.as of 30 Nov 2023 | 1.90m | 5.74% |
| PRIMECAP Management Co.as of 24 Mar 2023 | 1.06m | 3.20% |
| Newtyn Management LLCas of 12 Mar 2024 | 996.79k | 3.01% |
| T. Rowe Price International Ltd.as of 04 Jan 2023 | 990.44k | 2.99% |
| The Vanguard Group, Inc.as of 09 May 2024 | 540.79k | 1.63% |
| BlackRock Investment Management (UK) Ltd.as of 30 Apr 2024 | 379.27k | 1.15% |
| HBM Partners AG (Investment Management)as of 31 Dec 2023 | 320.00k | 0.97% |
| Credit Suisse Asset Management (Schweiz) AGas of 29 Feb 2024 | 267.70k | 0.81% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 242.73k | 0.73% |
| UBS Asset Management Switzerland AGas of 07 May 2024 | 225.92k | 0.68% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
